联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4252人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313781, encodeId=b7b21313e818e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Clin cancer res：FTD/TPI+伊立替康+贝伐单抗联合治疗晚期消化道肿瘤的疗效和安全性, objectType=article, longId=191573, objectId=25001915e376, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25001915e376, replyNumber=0, likeNumber=76, createdTime=2020-04-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25001915e376, moduleTitle=Clin cancer res：FTD/TPI+伊立替康+贝伐单抗联合治疗晚期消化道肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25001915e376)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313780, encodeId=20a11313e8091, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, objectType=article, longId=190904, objectId=3990190904f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3990190904f4, replyNumber=0, likeNumber=61, createdTime=2020-03-28, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3990190904f4, moduleTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3990190904f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313779, encodeId=df2a1313e7917, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Medicine：牙周正畸联合治疗对牙周炎症的影响, objectType=article, longId=190156, objectId=afa7190156b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afa7190156b1, replyNumber=0, likeNumber=59, createdTime=2020-03-18, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afa7190156b1, moduleTitle=Medicine：牙周正畸联合治疗对牙周炎症的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afa7190156b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313778, encodeId=987b1313e783e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤, objectType=article, longId=188065, objectId=7e7c18806539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e7c18806539, replyNumber=0, likeNumber=56, createdTime=2020-02-16, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e7c18806539, moduleTitle=强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e7c18806539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313777, encodeId=608b1313e775c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=抑癌基因疗法Oncoprex与Osimertinib联合治疗非小细胞肺癌（NSCLC）, objectType=article, longId=187589, objectId=add618e5896e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=add618e5896e, replyNumber=0, likeNumber=61, createdTime=2020-02-08, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=add618e5896e, moduleTitle=抑癌基因疗法Oncoprex与Osimertinib联合治疗非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=add618e5896e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313776, encodeId=4f7c1313e76a2, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Chest：吸入性糖皮质激素和长效β2激动剂联合治疗慢性阻塞性肺疾病的安全性和疗效, objectType=article, longId=185417, objectId=2bb918541e74, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bb918541e74, replyNumber=0, likeNumber=46, createdTime=2019-12-31, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bb918541e74, moduleTitle=Chest：吸入性糖皮质激素和长效β2激动剂联合治疗慢性阻塞性肺疾病的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bb918541e74)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313775, encodeId=1ad31313e759a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展, objectType=article, longId=184424, objectId=be5518442420, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be5518442420, replyNumber=0, likeNumber=120, createdTime=2019-12-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be5518442420, moduleTitle=聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be5518442420)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313774, encodeId=4c201313e7476, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=阿扎胞苷联合治疗助力AML疗效再度升级, objectType=article, longId=184370, objectId=c09a1843e0ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c09a1843e0ac, replyNumber=0, likeNumber=78, createdTime=2019-12-08, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c09a1843e0ac, moduleTitle=阿扎胞苷联合治疗助力AML疗效再度升级, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c09a1843e0ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313773, encodeId=84c81313e7328, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=2019年SNO年会：DNX-2401与pembrolizumab联合治疗胶质母细胞瘤的II期研究取得积极结果, objectType=article, longId=183566, objectId=9e51183566d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e51183566d3, replyNumber=0, likeNumber=73, createdTime=2019-11-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e51183566d3, moduleTitle=2019年SNO年会：DNX-2401与pembrolizumab联合治疗胶质母细胞瘤的II期研究取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e51183566d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313772, encodeId=7e711313e727e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Oncolytics宣布溶瘤病毒Pelareorep与Keytruda联合治疗晚期胰腺癌的阳性1b期REO 024研究结果, objectType=article, longId=182557, objectId=95c618255ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95c618255ecd, replyNumber=0, likeNumber=64, createdTime=2019-11-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95c618255ecd, moduleTitle=Oncolytics宣布溶瘤病毒Pelareorep与Keytruda联合治疗晚期胰腺癌的阳性1b期REO 024研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95c618255ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313771, encodeId=ba141313e7113, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性, objectType=article, longId=182514, objectId=bed218251491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed218251491, replyNumber=0, likeNumber=57, createdTime=2019-11-08, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed218251491, moduleTitle=BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed218251491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313770, encodeId=31f21313e703a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Mallinckrodt的UVADEX（甲氧沙林）获得澳大利亚批准，与THERAKOS CELLEX光电穿刺系统联合治疗成人慢性移植物抗宿主疾病和T细胞淋巴瘤, objectType=article, longId=182364, objectId=2e5e18236425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e5e18236425, replyNumber=0, likeNumber=30, createdTime=2019-11-06, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e5e18236425, moduleTitle=Mallinckrodt的UVADEX（甲氧沙林）获得澳大利亚批准，与THERAKOS CELLEX光电穿刺系统联合治疗成人慢性移植物抗宿主疾病和T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e5e18236425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313769, encodeId=01551313e693e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=肺癌诊疗发展不断突破，抗血管生成联合治疗值得期待, objectType=article, longId=182239, objectId=a7a9182239f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7a9182239f8, replyNumber=0, likeNumber=131, createdTime=2019-11-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7a9182239f8, moduleTitle=肺癌诊疗发展不断突破，抗血管生成联合治疗值得期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7a9182239f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313768, encodeId=19411313e6878, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：纳武单抗和伊匹单抗联合治疗对晚期黑色素瘤患者五年存活率的影响, objectType=article, longId=181443, objectId=a3471814437b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3471814437b, replyNumber=0, likeNumber=79, createdTime=2019-10-18, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3471814437b, moduleTitle=NEJM：纳武单抗和伊匹单抗联合治疗对晚期黑色素瘤患者五年存活率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3471814437b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313767, encodeId=abc41313e6789, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ESMO重磅：一线双免疫联合治疗完胜化疗, objectType=article, longId=181033, objectId=fe5d181033f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe5d181033f2, replyNumber=0, likeNumber=60, createdTime=2019-10-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe5d181033f2, moduleTitle=ESMO重磅：一线双免疫联合治疗完胜化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe5d181033f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313766, encodeId=8ef01313e66fb, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Sci Rep：新的胰腺癌联合治疗方案可逆转肿瘤微环境！, objectType=article, longId=180988, objectId=170a18098829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=170a18098829, replyNumber=0, likeNumber=78, createdTime=2019-10-13, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=170a18098829, moduleTitle=Sci Rep：新的胰腺癌联合治疗方案可逆转肿瘤微环境！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=170a18098829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313765, encodeId=ad911313e6506, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Cell Rep：新的胰腺癌联合治疗方案可逆转肿瘤微环境, objectType=article, longId=180970, objectId=7d251809e0e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d251809e0e7, replyNumber=0, likeNumber=65, createdTime=2019-10-13, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d251809e0e7, moduleTitle=Cell Rep：新的胰腺癌联合治疗方案可逆转肿瘤微环境, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d251809e0e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313764, encodeId=2ce41313e64fe, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS, objectType=article, longId=180458, objectId=cfa118045850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfa118045850, replyNumber=0, likeNumber=68, createdTime=2019-10-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfa118045850, moduleTitle=“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfa118045850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313763, encodeId=61691313e6345, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Allergy Rhinol：内窥镜手术和外部切除手术联合治疗泪囊乳头状瘤, objectType=article, longId=180207, objectId=bd7d18020e1e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd7d18020e1e, replyNumber=0, likeNumber=77, createdTime=2019-09-30, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd7d18020e1e, moduleTitle=Allergy Rhinol：内窥镜手术和外部切除手术联合治疗泪囊乳头状瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd7d18020e1e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313762, encodeId=30e31313e620a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JACC：利伐沙班和阿司匹林联合治疗明显增加胃肠出血风险, objectType=article, longId=179917, objectId=49e41e9917a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49e41e9917a4, replyNumber=0, likeNumber=66, createdTime=2019-09-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49e41e9917a4, moduleTitle=JACC：利伐沙班和阿司匹林联合治疗明显增加胃肠出血风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49e41e9917a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#联合治疗#

Clin cancer res：FTD/TPI+伊立替康+贝伐单抗联合治疗晚期消化道肿瘤的疗效和安全性

2020-04-08

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局

2020-03-28

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Medicine：牙周正畸联合治疗对牙周炎症的影响

2020-03-18

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤

2020-02-16

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

抑癌基因疗法Oncoprex与Osimertinib联合治疗非小细胞肺癌（NSCLC）

2020-02-08

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Chest：吸入性糖皮质激素和长效β2激动剂联合治疗慢性阻塞性肺疾病的安全性和疗效

2019-12-31

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展

2019-12-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

阿扎胞苷联合治疗助力AML疗效再度升级

2019-12-08

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

2019年SNO年会：DNX-2401与pembrolizumab联合治疗胶质母细胞瘤的II期研究取得积极结果

2019-11-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Oncolytics宣布溶瘤病毒Pelareorep与Keytruda联合治疗晚期胰腺癌的阳性1b期REO 024研究结果

2019-11-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性

2019-11-08

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Mallinckrodt的UVADEX（甲氧沙林）获得澳大利亚批准，与THERAKOS CELLEX光电穿刺系统联合治疗成人慢性移植物抗宿主疾病和T细胞淋巴瘤

2019-11-06

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

肺癌诊疗发展不断突破，抗血管生成联合治疗值得期待

2019-11-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：纳武单抗和伊匹单抗联合治疗对晚期黑色素瘤患者五年存活率的影响

2019-10-18

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ESMO重磅：一线双免疫联合治疗完胜化疗

2019-10-14

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Sci Rep：新的胰腺癌联合治疗方案可逆转肿瘤微环境！

2019-10-13

柳叶一刀 (审核中...)

前往app查看评论内容

#联合治疗#

Cell Rep：新的胰腺癌联合治疗方案可逆转肿瘤微环境

2019-10-13

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS

2019-10-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Allergy Rhinol：内窥镜手术和外部切除手术联合治疗泪囊乳头状瘤

2019-09-30

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JACC：利伐沙班和阿司匹林联合治疗明显增加胃肠出血风险

2019-09-25

科室
- - 订阅+
  - 更多科室
工具
服务